Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Abstract

Activating mutations of <i>KIT</i> or <i>PDGFRA</i> are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib. <i>PDGFRA</i> mutations can explain response and sensitivity to imatinib in some GISTs lacking <i>KIT</i> mutations.